Laura Gálvez - Concepedia

Author

Laura Gálvez

Instituto de Investigación Biomédica de Málaga ORCID

Also Known As

L. Galvez Carvajal, L. Galvez-Carvajal, L. Galvez‐Carvajal, L. Gálvez, L. Gálvez Carvajal, L. Gálvez-Carvajal, Laura G. Carvajal, Laura Galvez, Laura Galvez Carvajal, Laura Galvez-Carvajal

Publications

353

Citations

H-Index

Concepts

All Affiliations

Instituto de Investigación Biomédica de Málaga Universidad de Málaga Hospital Del Mar Hospital Universitari i Politècnic La Fe Hospital Universitario Puerta de Hierro Majadahonda

About

Laura Gálvez is an author at Instituto de Investigación Biomédica de Málaga specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	125
2	Engineering	1	1	23
3	Public Health	1	1	32
4	Cell Biology	1	1	28
5	Health Informatics	1	1	23

Laura Gálvez

Publications

270

Citations

H-Index

Page 1

	Year	Citations
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial Carlos Jiménez‐Cortegana, Natalia Palazón‐Carrión, Alejandro Martı́n, Journal for ImmunoTherapy of Cancer	2021	60
Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study Ismael Fernández‐Miranda, Lucía Pedrosa, Marta Llanos, Clinical Cancer Research Cancer PathologyImmunologyPathologyImmunophenotypingBasal Cfdna	2022	42
Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study Sofía Ruiz-Medina, S Justo Gil, Begoña Jiménez, Cancers	2021	36
Identification of Novel microRNA Profiles Dysregulated in Plasma and Tissue of Abdominal Aortic Aneurysm Patients Emma Plana, Laura Gálvez, Pilar Medina, International Journal of Molecular Sciences Vascular DiseaseImmunologyPathologyAaa PatientsInflammation	2020	32
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade Juan Luis Onieva, Qingyang Xiao, Miguel‐Ángel Berciano‐Guerrero, International Journal of Molecular Sciences ImmunologyPathologyImmunologic MechanismImmune Cell TherapyImmunotherapy	2022	28
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients Nuria Ribelles, José M. Jerez, Pablo Rodríguez-Brazzarola, European Journal of Cancer Natural Language ProcessingBreast OncologyOncologyMachine LearningEngineering	2020	23
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis Natalia Palazón‐Carrión, Alejandro Martı́n, Esteban Nogales‐Fernández, Clinical Cancer Research	2022	15
Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL) Franck Morschhauser, Krish Patel, Sabela Bobillo, Blood	2023	14
Risk patterns in food addiction: a Mexican population approach Lucero Munguía, Susana Jiménez‐Múrcia, Eduardo Valenciano‐Mendoza, Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity	2021	10
Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study Nuria Ribelles, Javier Pascual, Laura Gálvez, JCO Global Oncology	2024	10

Page 1